Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Manosuthi, Weerawat ^a,b   Kiertiburanakul, Sasisopin ^b   Amornnimit, Wannarat ^a   Prasithsirikul, Wisit ^a   Thongyen, Supeda ^a   Nilkamhang, Samruay ^a   Ruxrungtham, Kiat ^c,d   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79953145605     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-6-30     Document Type: Article

References (21)

1. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a public Health Approach. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); 2006 revision.
2. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007, 44(3):447-452. 10.1086/510745, 17205457.
3. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008, 47(2):266-285. 10.1086/589297, 18549313.
4. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006, 296(7):827-843. 10.1001/jama.296.7.827, 16905788.
5. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U. S. Department of Health and Human Services (DHHS). , http://AIDSinfo.nih.gov
6. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009, 23(3):279-291. 10.1097/QAD.0b013e32831c54e5, 19114854.
7. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006, 20(6):795-803. 10.1097/01.aids.0000218542.08845.b2, 16549962.
8. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, Chetchotisakd P, Kiertiburanakul S, Tansuphaswadikul S, Buppanharun W, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008, 91(12):1925-1935.
9. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003, 25(3):393-399. 10.1097/00007691-200306000-00023, 12766571.
10. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008, 22(3):385-393. 10.1097/QAD.0b013e3282f3f16d, 18195565.
11. Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009, 50(5):474-481. 10.1097/QAI.0b013e31819c2937, 19225400.
12. Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis 2005, 192(8):1407-1411. 10.1086/466537, 16170758.
13. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006, 20(3):371-377. 10.1097/01.aids.0000196180.11293.9a, 16439870.
14. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358(20):2095-2106. 10.1056/NEJMoa074609, 18480202.
15. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007, 21(10):1309-1315. 10.1097/QAD.0b013e32814e6b1c, 17545707.
16. Nijhuis M, van Maarseveen NM, Verheyen J, Boucher CA. Novel mechanisms of HIV protease inhibitor resistance. Curr Opin HIV AIDS 2008, 3(6):627-632. 10.1097/COH.0b013e3283136cd9, 19373034.
17. Atkinson MJ, Petrozzino JJ. An Evidence-Based Review of Treatment-Related Determinants of Patients' Nonadherence to HIV Medications. AIDS Patient Care STDS 2009, 23(11):903-14. 10.1089/apc.2009.0024, 19642921.
18. Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005, 56(2):273-276. 10.1093/jac/dki209, 15994247.
19. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003, 63(8):769-802. 10.2165/00003495-200363080-00004, 12662125.
20. Scranton R, Sesso HD, Stampfer MJ, Levenson JW, Buring JE, Gaziano JM. Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men. Am Heart J 2004, 147(6):1033-1038. 10.1016/j.ahj.2003.11.018, 15199352.
21. Kosuge M, Kimura K, Ishikawa T, Shimizu T, Sugano T, Sumita S, Hibi K, Takamura T, Toda N, Kanna M, et al. Different clinical and coronary angiographic findings according to ratios of total cholesterol to high-density lipoprotein cholesterol during the acute phase of myocardial infarction. J Cardiol 2004, 43(6):251-258.